Abstract
Background SeptiCyte RAPID is a molecular test for distinguishing sepsis from non-infectious systemic inflammation. The objective of this study was the clinical validation of SeptiCyte RAPID, based on testing retrospective (banked) and prospectively collected patient samples.
Methods Testing retrospective (banked) and prospective samples from adult patients in ICU either having systemic inflammatory response syndrome (SIRS) or suspected of sepsis. Test results were compared to a “gold standard” of clinical evaluation by a blinded three physician external panel.
Results The cartridge-based SeptiCyte RAPID assay accepts a PAXgene blood RNA sample and provides sample-to-answer processing in ∼1 hour. The test output (SeptiScore, range 0-15) falls into four interpretation bands, with higher scores indicating higher probabilities of sepsis. SeptiCyte RAPID performance is comparable to that for SeptiCyte LAB, with Area Under the ROC Curve (AUC) ranging from 0.82 – 0.85, negative predictive value 0.91 (sensitivity 0.94) for SeptiScores between 0.1 and 5.0 (Band 1, lowest risk of sepsis), and positive predictive value 0.81 (specificity 0.90) for SeptiScores between 7.4 and 15 (Band 4, highest risk of sepsis). For all blood culture confirmed sepsis cases, SeptiCyte RAPID indicated an elevated risk of sepsis with 34/38 (90%) of scores falling in bands 3 or 4. In multivariable analysis, SeptiScore was the most important variable for sepsis diagnosis. A likelihood ratio method was developed to estimate the post-test probability of sepsis for individual patients, when combining the SeptiScore with additional clinical parameters.
Conclusions This study validates SeptiCyte RAPID for differentiating patients with sepsis vs. SIRS, on the first day of ICU admission.
Trial Registration NCT01905033 (MARS), NCT02127502 (VENUS), NCT05469048 (NEPTUNE, retrospectively registered) at clinicaltrials.gov.
Competing Interest Statement
The following coauthors are employees and/or shareholders of Immunexpress: Krupa Navalkar, Thomas D. Yager, Dayle Sampson, James T. Kirk, Silvia Cermelli, Roy F. Davis, Richard B. Brandon
Funding Statement
This study was funded by Immunexpress, Inc.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for this work has been granted by the following ethics committees/IRBs: Amsterdam Medical Center (10-056C), Intermountain Medical Center/Latter Day Saints Hospital (1024931); Johns Hopkins Hospital (IRB00087839); Rush University Medical Center (15111104-IRB01 & 19101603-IRB01); Loyola University Medical Center (208291); Northwell Healthcare (16-02-42-03); Grady Memorial Hospital (000-87806 & 00-115400), Emory University (IRB00115400), University of Southern California Medical Center (HS-19-0884-CR001).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
This article has Supplementary Information, which is accessible online and linked to the article.
Sources of Support: This study was supported by Immunexpress Inc.
Best Descriptor: CRITICAL CARE, 4.12 Sepsis/Multiple Organ Failure
Main document: Statistical analysis in Table 1 updated; Figures 2, 3, 4, 5 updated; text clarified in multiple places. Supplement: Section 3 expanded, and new Sections 1, 4, 5, 6 added (see revised Table of Contents); text clarified in multiple places.
Data Availability
Data produced in the present study are available upon reasonable request to the authors.
Abbreviations
- %A
- Percent Agreement
- ANOVA
- Analysis of Variance
- AUC
- Area Under (Receiver Operator Characteristic) Curve
- CAD
- Coronary artery disease
- CKD
- Chronic kidney disease
- CPAP
- Continuous positive airway pressure
- Cq
- Quantification Cycle (for PCR)
- CRP
- C-Reactive Protein
- ED
- Emergency Department
- ICU
- Intensive Care Unit
- IQR
- Interquartile Range
- Ku
- Unweighted inter-observer kappa
- Kw
- Linearly weighted inter-observer kappa
- LR
- Likelihood Ratio
- PCR
- Polymerase Chain Reaction
- PCT
- Procalcitonin
- PLA2G7
- Phospholipase A2, Group VII
- PLAC8
- Placenta associated 8
- ROC
- Receiver Operator Characteristic (curve)
- RPD
- Retrospective Physician Diagnosis
- RT-qPCR
- Reverse Transcription - Quantitative Polymerase Chain Reaction
- SIRS
- Systemic Inflammatory Response Syndrome
- SSC
- Surviving Sepsis Campaign
- Tukey HSD
- Tukey Honestly Significant Difference
- WBC
- White Blood Cell
